Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Ultragenyx Pharmaceutical Inc. Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and...
Ultragenyx Pharmaceutical Inc. Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and...
In her new book, “Breaking Ground,” the legal marketing expert shares her best advice and that of 60 of the...
Small businesses in the food industry often encounter a lot of competition. Larger restaurants and food chains can afford more...
With reports showing 2025 had the weakest job growth since 2003, political unrest in the U.S. and abroad, layoffs and...
Supporting strategic growth: Housing, retail and cost-effective development Published 3:00 pm Monday, January 12, 2026 During the past year, residents...
Secondary offerings were up 76% last year to $23.6 billion, while initial public offerings (IPOs) jumped by 243% from the...
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the...
As customer attention fragments and marketing costs rise, relationship-driven growth has become one of the most effective ways for businesses...
Uneven cash flow stemming from late payments and limited access to funding is more than a bump in the road...